Evidence map›Paper›PMID 38182915›Full record

ArticleNature cancer2024

Author Correction: Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.

Caicun Zhou, Ziping Wang, Meili Sun, Lejie Cao, Zhiyong Ma, Rong Wu, Yan Yu, Wenxiu Yao, Si Sun, Jianhua Chen and 24 more

Open access · bronzeAbstract readPublished Erratum
PubMed Publisher
In one paragraph

Article in Nature cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 20 institutions in 1 country.

Caicun ZhouDepartment of Oncology, Shanghai Pulmonary Hospital, School of Medicine Tongji University, Shanghai, China. caicunzhoudr@163.com.ORCID http://orcid.org/0000-0002-6958-0766
Ziping WangKey Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Thoracic Oncology, Peking University Cancer Hospital and Institute, Beijing, China.
Meili SunDepartment of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China.
Lejie CaoDepartment of Respiratory Medicine, The First Affiliated Hospital of University of Science and Technology of China, Division of Life Sciences and Medicine, University of Science and Technology of China, Anhui Provincial Hospital, Hefei, China.
Zhiyong MaDepartment of Respiratory Medicine, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China.
Rong WuDepartment of Oncology, Shengjing Hospital of China Medical University, Huaxiang Branch Hospital, Shenyang, China.
Yan YuDepartment of Respiratory Medicine, Harbin Medical University Cancer Hospital, Harbin, China.
Wenxiu YaoThoracic Oncology, Sichuan Cancer Hospital and Institute, Chengdu, China.
Si SunDepartment of Oncology, Fudan University Shanghai Cancer Centre, Shanghai, China.
Jianhua ChenDepartment of Thoracic Oncology, Hunan Cancer Hospital, Changsha, China.
Wu ZhuangDepartment of Thoracic Oncology, Fujian Provincial Cancer Hospital, Fuzhou, China.
Jiuwei CuiPharmacology Base, The First Hospital of Jilin University, Changchun, China.
Xueqin ChenDepartment of Thoracic Oncology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Zhejiang University Cancer Centre, Hangzhou, China.
You LuDepartment of Thoracic Oncology, West China Hospital, Sichuan University, Chengdu, China.ORCID http://orcid.org/0000-0003-1671-1408
Hong ShenDepartment of Oncology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
Chunhong HuDepartment of Oncology, The Second Xiangya Hospital of Central South University, Changsha, China.
Jiwei LiuDepartment of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, China.
Yunpeng LiuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
Mengzhao WangDepartment of Respiratory and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Xingya LiDepartment of Medical Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Ping SunDepartment of Oncology, Yantai Yuhuangding Hospital, Yantai, China.
Yongqian ShuMedical Oncology, Jiangsu Province Hospital, Nanjing, China.
Jianying ZhouDepartment of Respiratory Disease, Thoracic Disease Centre, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Jingzhang LiDepartment of Oncology, Liuzhou General Hospital, Liuzhou, China.
Kangsheng GuDepartment of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Changli WangDepartment of Lung Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Hui ZhaoDepartment of Respiratory Medicine, The Second Hospital of Anhui Medical University, Hefei, China.
Yiping ZhangDepartment of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, China.
Chunling LiuThe Second Department of Pulmonary Medicine, The Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China.
Jingru WangClinical Development, CStone Pharmaceuticals, Suzhou, China.
Rumei ChenClinical Development, CStone Pharmaceuticals, Suzhou, China.
Mengmeng QinClinical Development, CStone Pharmaceuticals, Suzhou, China.
Hao WangClinical Development, CStone Pharmaceuticals, Suzhou, China.
Jason YangClinical Development, CStone Pharmaceuticals, Suzhou, China.
Anhui Medical University · CNCentral South University · CNChina Medical University · CNChinese Academy of Medical Sciences & Peking Union Medical College · CNDalian Medical University · CNFirst Affiliated Hospital of Zhengzhou University · CNFirst Hospital of China Medical University · CNFudan University Shanghai Cancer Center · CNFujian Provincial Cancer Hospital · CNHangzhou First People's Hospital · CNHarbin Medical University · CNHunan Cancer Hospital · CNJiangsu Province Hospital · CNJilin University · CNLiuzhou General Hospital · CNPeking University · CNSecond Affiliated Hospital of Zhejiang University · CNShandong University · CNSichuan Cancer Hospital · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID38182915
OpenAlexW4390618789

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.